EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan

Yaride Pérez-Pacheco iD, Deepak Parajuli iD, Ricard García-Valls

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yaride Pérez-Pacheco und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Universitat Rovira i Virgili, Campus Sescelades, Av. Països Catalans 26, 43007 Tarragona, Spain. Hauptthemen laut MEDLINE: Chitosan, Nanomedicine, Drug Carriers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic diseases such as cancer, cardiovascular disorders, neurodegenerative conditions, chronic respiratory diseases, autoimmune disorders, chronic kidney disease, persistent infectious diseases, diabetes, and ocular inflammation remain leading causes of morbidity and mortality worldwide. Their complex pathophysiologies and the limitations of conventional therapies underscore the urgent need for advanced drug delivery platforms that enhance therapeutic efficacy while minimizing off-target effects and systemic toxicity leading to adverse reactions. Nanomedicine has emerged as a transformative approach, with chitosan-based nanocarriers offering advantages due to their biocompatibility, biodegradability, mucoadhesive properties, and ability to be physic-chemically modified. These nanocarriers improve solubility, stability, bioavailability, and the therapeutic index of drugs, while enabling controlled release, targeted delivery, and immune modulation. This review highlights recent advances in chitosan-based nanomedicine for the management of chronic disease. We discuss methods of synthesis such as ionic gelation and electrospray, functionalization approaches, and immunomodulatory roles that expand therapeutic potential. The evidence emphasizes that chitosan nanocarriers are a versatile, safe, and effective platform which can be used to improve clinical results, reduce adverse effects, and advance the science of personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChitosanNanomedicineDrug CarriersHumansChronic DiseaseAnimalsDrug Delivery SystemsNanoparticles

Stichwörter der Autor:innen

chitosan nanocarrierschronic diseaseencapsulationpersonalized medicinetargeted drug delivery

Substanzen

ChitosanDrug Carriers

Autor:innen und Institutionen

  • Department of Chemical Engineering, Universitat Rovira i Virgili, Campus Sescelades, Av. Països Catalans 26, 43007 Tarragona, Spain.

ORCID-Profile: Yaride Pérez-Pacheco, Deepak Parajuli

Zitieren

APA

Pérez-Pacheco, Y., Parajuli, D., & García-Valls, R. (2026). Emerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031387

Vancouver

Pérez-Pacheco Y, Parajuli D, García-Valls R. Emerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031387

BibTeX
@article{PrezPacheco2026,
  author = {Pérez-Pacheco, Yaride and Parajuli, Deepak and García-Valls, Ricard},
  title = {Emerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031387}
}
Kostenlos starten →